Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction.

Olsson-Brown A, Lord R, Sacco J, Wagg J, Coles M, Pirmohamed M.

Endocr Connect. 2020 Mar 1. pii: EC-19-0473.R1. doi: 10.1530/EC-19-0473. [Epub ahead of print]

2.

Immune dysregulation increases the incidence of delayed-type drug hypersensitivity reactions.

Naisbitt DJ, Olsson-Brown A, Gibson A, Meng X, Ogese MO, Tailor A, Thomson P.

Allergy. 2019 Nov 23. doi: 10.1111/all.14127. [Epub ahead of print] Review.

PMID:
31758810
3.

The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool.

Olsson-Brown A, Piskilidis P, O'Hagan J, Thorp N, Robson P, Innes H, Wong H, Cicconi S, Jackson R, Kiernan T, Holcombe C, O'Reilly S, Palmieri C.

Breast. 2019 Apr;44:94-100. doi: 10.1016/j.breast.2019.01.005. Epub 2019 Jan 18.

PMID:
30703670
4.

How to get started in quality improvement.

Jones B, Vaux E, Olsson-Brown A.

BMJ. 2019 Jan 17;364:k5408. doi: 10.1136/bmj.k5437. No abstract available.

5.

Using QR codes to enable quick access to information in acute cancer care.

Upton J, Olsson-Brown A, Marshall E, Sacco J.

Br J Nurs. 2017 May 25;26(10):S4-S12. doi: 10.12968/bjon.2017.26.10.S4.

PMID:
28541108

Supplemental Content

Loading ...
Support Center